96 related articles for article (PubMed ID: 9600636)
1. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
4. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
[TBL] [Abstract][Full Text] [Related]
7. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery.
Kawano K; Ikeda Y; Kondo K; Umemura K
Eur J Pharmacol; 1999 Jun; 374(3):377-85. PubMed ID: 10422782
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys.
Suzuki K; Sakai Y; Hisamichi N; Taniuchi Y; Sato K; Terazaki C; Kaku S; Kawasaki T; Yano S; Inagaki O; Masuho Y
Eur J Pharmacol; 1997 Oct; 336(2-3):169-76. PubMed ID: 9384230
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Imura Y; Kiyota Y; Nagai Y; Nishikawa K; Terashita Z
Thromb Res; 1995 Jul; 79(1):95-107. PubMed ID: 7495108
[TBL] [Abstract][Full Text] [Related]
11. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
Imamura T; Kiguchi S; Kobayashi K; Ichikawa K; Yamazaki Y; Kojima M
Arzneimittelforschung; 2003; 53(10):688-94. PubMed ID: 14650360
[TBL] [Abstract][Full Text] [Related]
12. Effect of TTC-909 in a middle cerebral artery thrombosis model in stroke-prone spontaneously hypertensive rats.
Karasawa Y; Hitomi T; Komiyama H; Isobe Y; Kobayashi T; Yoshida S; Nakaike S; Araki H
Eur J Pharmacol; 2002 Aug; 449(1-2):127-133. PubMed ID: 12163116
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
Graff J; Klinkhardt U; Westrup D; Kirchmaier CM; Breddin HK; Harder S
Br J Clin Pharmacol; 2003 Sep; 56(3):321-6. PubMed ID: 12919181
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Umemura K; Wada K; Uematsu T; Nakashima M
Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
[TBL] [Abstract][Full Text] [Related]
15. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I
J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166
[TBL] [Abstract][Full Text] [Related]
16. The effect of ozagrel sodium on photochemical thrombosis in rat: therapeutic window and combined therapy with heparin sodium.
Arii K; Igarashi H; Arii T; Katayama Y
Life Sci; 2002 Nov; 71(25):2983-94. PubMed ID: 12384182
[TBL] [Abstract][Full Text] [Related]
17. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the antiplatelet effects of a humanized anti-platelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions.
Kuwahara M; Sugimoto M; Tsuji S; Miyata S; Nishio K; Kaku S; Suzuki K; Kawasaki T; Yoshioka A
Thromb Haemost; 1998 Jul; 80(1):28-31. PubMed ID: 9684780
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys.
Kaku S; Kawasaki T; Sakai Y; Taniuchi Y; Yano S; Suzuki K; Terazaki C; Kawamura K; Masuho Y; Satoh N
Eur J Pharmacol; 1995 Jun; 279(2-3):115-21. PubMed ID: 7556391
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction.
Oishi M; Mochizuki Y; Hara M; Yoshihashi H; Takasu T
Clin Neuropharmacol; 1996 Dec; 19(6):526-31. PubMed ID: 8937792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
